Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715467 | 0.81 | CYP1A2 (0.80) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL14916729 | 0.78 | CYP1A2 (0.75) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL12456470 | 0.77 | CYP1A2 (0.56) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL12456039 | 0.77 | GAA (0.52) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL14916613 | 0.75 | CYP1A2 (0.65) | CYP1A2GAAJAK3PDE4ACTSK | |
| SCHEMBL2538688 | 0.73 | CYP1A2 (0.72) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL12456469 | 0.72 | CYP1A2 (0.65) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 | |
| SCHEMBL2534556 | 0.72 | CYP1A2 (0.70) | CYP1A2GAAPDE4ASMN1; SMN2 | |
| SCHEMBL12456041 | 0.71 | GAA (0.61) | CYP1A2GAAPDE4ASMN1; SMN2 | |
| SCHEMBL2126554 | 0.71 | CYP1A2 (0.68) | CYP1A2GAAJAK3PDE4ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885JAK3 2207/4885 |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885JAK3 2207/4885 |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885JAK3 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.